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OBJECTIVE—Investigating the dynamics of pancreatic b-cell
mass is critical for developing strategies to treat both type 1
and type 2 diabetes. p53, a key regulator of the cell cycle and
apoptosis, has mostly been a focus of investigation as a tumor
suppressor. Although p53 alternative transcripts can modulate
p53 activity, their functions are not fully understood. We hypoth-
esized that b-cell proliferation and glucose homeostasis were
controlled by D40p53, a p53 isoform lacking the transactivation
domain of the full-length protein that modulates total p53 activity
and regulates organ size and life span in mice.
RESEARCH DESIGN AND METHODS—We phenotyped met-
abolic parameters in D40p53 transgenic (p44tg) mice and used
quantitative RT-PCR, Western blotting, and immunohistochemis-
try to examine b-cell proliferation.
RESULTS—Transgenic mice with an ectopic p53 gene encoding
D40p53 developed hypoinsulinemia and glucose intolerance by
3 months of age, which worsened in older mice and led to overt
diabetes and premature death from ;14 months of age. Consis-
tent with a dramatic decrease in b-cell mass and reduced b-cell
proliferation, lower expression of cyclin D2 and pancreatic duo-
denal homeobox-1, two key regulators of proliferation, was ob-
served, whereas expression of the cell cycle inhibitor p21, a p53
target gene, was increased.
CONCLUSIONS—These data indicate a signiﬁcant and novel role
for D40p53 in b-cell proliferation with implications for the develop-
ment of age-dependent diabetes. Diabetes 60:1210–1222, 2011
T
he maintenance of adult b-cell mass is critical for
the appropriate regulation of glucose homeosta-
sis in both humans and rodents. b-Cell replica-
tion is generally accepted as essential for b-cell
expansion after birth but remains controversial in adult
b-cells (1–7). Nevertheless, a recent study highlighted the
ability of human b-cells to replicate in response to com-
bined expression of two cell cycle regulators (8).
Cell replication is regulated by a balance between the
active cyclin-cyclin dependent kinase (CDK) complexes and
CDK inhibitors, which regulate phosphorylation of retino-
blastoma protein, S-phase entry, and cell cycle progression
(4). Among the cell cycle proteins regulating the G1 to
S phase transition, CDK4 and cyclin D2 are particularly
important. Mice deﬁcient in CDK4 develop b-cell hypo-
plasia and diabetes (9,10); conversely, overexpression of
CDK4 in transgenic mice causes islet hyperplasia without
hypoglycemia (9). Cyclin D2, the most abundant cyclin in
the islet, has been reported to be critical for postnatal
pancreatic b-cell growth (5,11). Global loss of cyclin D2
in mice causes loss of b-cell mass, glucose intolerance,
and age-dependent diabetes (5,11), whereas absence of
cyclin D2 prevents the expansion of b-cell mass in re-
sponse to a spectrum of insulin resistance (12). Further-
more, transplantation of human islets transduced with
cyclin D1 and CDK6 (expressed in humans but not rodent
islets) into diabetic mice improved blood glucose (8).
Other reports indicate that Akt is important for the reg-
ulation of cyclin D1, cyclin D2, and CDK4 (13), and con-
ﬁrm a link between cell cycle progression and insulin/
IGF-1 signaling, a pathway critical for b-cell growth and
function (14–17).
The tumor suppressor p53 is a transcription factor and
a global suppressor of cell cycle genes, such as cyclins and
CDKs (18), and also can actively block cell cycle pro-
gression by transactivating its main target gene p21 (19).
Mice deﬁcient in p53 are developmentally normal, but
show an increased risk of developing spontaneous tumors
in diverse tissues as they age (20,21), but they do not de-
velop insulinomas. Although most studies have focused on
p53 action in the context of tumor formation and apopto-
sis, the key role of p53 in cell growth suggests that the
protein may participate in b-cell cycle control and conse-
quently contribute to glucose homeostasis.
The current study investigated the importance of p53 in
b-cell growth using mice carrying an extra copy of p53 that
codes for D40p53, a 44 kD isoform of p53, also described
as DNp53 or p44 (mouse)/p47(human), that lacks the ﬁrst
40 amino acids of the full-length protein (22). Indeed, up to
10 p53 isoforms have been recently identiﬁed indicat-
ing the complex regulation of p53 (23). Inappropriate ex-
pression of D40p53 alters the balance that normally exists
between the isoforms and stabilizes full-length p53. Stabi-
lization of p53 in p44 transgenic (p44tg) mice confers in-
creased tumor suppression, but also results in accelerated
aging and is associated with abnormal insulin/IGF-1 sig-
naling (22) and impaired cell proliferation (24). Because
aging is an important risk factor for the development of
type 2 diabetes (25,26), we used this model of accelerated
aging to investigate the role of p53 in islet/b-cell growth.
We report that misexpression of D40p53 in p44tg mice
is associated with early hypoinsulinemia and glucose
intolerance that worsens with age and leads to overt hy-
perglycemia and a dramatic decrease in b-cell prolifera-
tion. These data suggest that the coordinated activity of
p53 isoforms, in particular that of D40p53 and full-length
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ORIGINAL ARTICLEp53, is necessary for the maintenance of b-cell mass during
aging, a ﬁnding that could have implications for the pre-
vention of age-dependent diabetes.
RESEARCH DESIGN AND METHODS
Animals and physiological measurements. p44tg mice were generated as
described previously (22). Data from male mice are reported. Body and pan-
creas weight were recorded, and blood glucose (Glucometer Elite, Bayer,
Terrytown, NJ), plasma insulin (enzyme-linked immunosorbent assay), and
glucagon (radioimmunoassay) levels (Joslin DERC Specialized Assay Core,
Boston, MA) were measured before experiments. Glucose tolerance tests,
acute glucose-stimulated insulin secretion (GSIS) tests, and insulin tolerance
tests were performed as previously reported (27). Pancreata were harvested
for immunohistochemical analyses and islet morphometry, and islets were
isolated for RNA extraction and in vitro GSIS on batches of 15 size-matched
islets as reported previously (28).
Islet morphology and immunohistochemistry. Pancreas sections were used
to assess b-cell mass and size as described previously (27). b-Cell proliferation
was assessed in pancreas sections as described previously (28), using anti-
insulin (guinea-pig antibody, DAKO, Carpinteria, CA), anti-BrdU (rabbit
polyclonal antibody, DAKO), or antiphosphohistone H3 antibodies (rabbit
polyclonal antibody, Upstate Biotechnology, Lake Placid, NY). Other anti-
bodies used include b-catenin (rabbit polyclonal antibody, BD Biosciences,
Oxford, U.K.), glucagon (mouse monoclonal antibody, Sigma-Aldrich, St. Louis,
MO), somatostatin (rabbit polyclonal antibody, Abcam, Cambridge, U.K.),
p21 (mouse monoclonal antibody, DAKO), insulin (mouse monoclonal antibody,
Biogenex, San Ramon, CA), and DAPI (Sigma-Aldrich) for nuclear staining.
Real-time RT-PCR. Quantitative real-time RT-PCR was performed on total
RNA samples extracted from islets and processed as described previously (28).
All primer sequences are available on request.
Western blot analysis. Western blotting was performed as described (3).
Antibodies used include cyclin D2 (rabbit polyclonal antibody, Santa Cruz
Biotechnology Inc., Santa Cruz, CA), FoxO1 (rabbit polyclonal antibody, Cell
Signaling, Danvers, MA), pancreatic duodenal homeobox-1 (PDX-1) (gift from
C.V. Wright, Vanderbilt University), p27 (mouse monoclonal antibody, BD
Biosciences), p21 (mouse monoclonal antibody, DAKO), and tubulin (mouse
monoclonal antibody, Abcam).
Statistical analyses. All data are presented as mean 6 SEM and were ana-
lyzed using an ANOVA or unpaired, two-tailed Student t test as appropriate.
A P value less than 0.05 was considered signiﬁcant. A minimum of n=3w a s
used for all studies unless indicated.
RESULTS
Glucose homeostasis and metabolic parameters. We
compared the phenotype of mice at 3, 10, and 12–14
months of age. The phenotype of p44tg mice becomes
evident at 3 months, and the animals begin to succumb at
;14 months of age (22). p44tg mice were lighter than their
nontransgenic counterparts at all ages, as shown for
3 months of age in Fig. 1A. The animals had already de-
veloped hypoinsulinemia at this age, which persisted
throughout life (Fig. 1C). Although the animals displayed
normal glucose tolerance at 2 months (Fig. 2A), they had
FIG. 1. p44tg mice exhibit hypoinsulinemia and hyperglycemia with age. Body weight (A), blood glucose (B), plasma insulin (C), and plasma
glucagon (D) levels were measured at 3, 10, and 12–14 months of age from random-fed control (□) and p44tg (■)( n=5–9) mice. *P < 0.05 for
p44tg vs. control mice. #P < 0.05 for control mice vs. different ages.
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diabetes.diabetesjournals.org DIABETES, VOL. 60, APRIL 2011 1211FIG. 2. p44tg mice exhibit age-dependent glucose intolerance and normal insulin sensitivity. Glucose tolerance tests performed at 2 months
(A), 3–5 months (B), and 10–14 months (C) of age (n=6–8). Blood glucose was measured at 0, 10, 20, 30, 60, and 120 min after intraperitoneal
injection of glucose. Insulin tolerance tests were performed in each group at 2 months (D), 3–4 months (E), and 15–16 months (F) of age (n=6–8).
Glucose was measured at 0, 15, 30, 45, and 60 min after intraperitoneal injection of insulin. IP, intraperitoneal; IPGTT, intraperitoneal glucose
tolerance test; IPITT, intraperitoneal insulin tolerance test. *P < 0.05 for p44tg vs. control mice.
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1212 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgFIG. 3. Age-dependent alterations in b-cell size in p44tg mice. A: Pancreatic weight expressed as a percentage of the total body weight (n=3).
B: b-Cell mass was assessed as described in RESEARCH DESIGN AND METHODS. C and D: b-Cell size was assessed by coimmunostaining for b-catenin
(green) and insulin (red) with DAPI (blue) in pancreas sections from control (n=5) and p44tg (n=5) mice at 3 and 12–14 months of age as
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signiﬁcantly hyperglycemic by 12–14 months (Fig. 1B and
2C), suggesting overt diabetes that could contribute, in
part, to death at this age. In contrast, all controls exhibited
fed blood glucose levels ,150 mg/dL at 12 months of age
(Fig. 1B). Glucagon levels were not signiﬁcantly different
between groups (Fig. 1D). Insulin sensitivity was unchanged
in p44tg mice from 3 months of age (Fig. 2E and F)a n de v e n
mildly improved in younger p44tg mice (Fig. 2D). These data
indicate that increased dosage of D40p53 leads to hypo-
insulinemia and glucose intolerance as early as 3 months
and worsens with age.
Disordered islet morphology in p44tg mice. Although
both pancreas weight and number of islets exhibited an
age-dependent increase in control mice, the total number
of islets was less in p44tg mice even when normalized to
total pancreas weight (Fig. 3A and Supplementary Fig. 1).
Compared with 3 months of age, the differences became
more marked at 12–14 months. The reduced pancreatic
weight and islet number in p44tg mice were associated
with a dramatic decrease in b-cell mass (Fig. 3B). Indeed,
b-cell mass was signiﬁcantly lower in the p44tg mice and
ranged between 11% (young) and 14% (old) in the age-
matched control animals. Quantiﬁcation of b-cell size
revealed a 30% decrease in the p44tg mice compared with
controls at 3 months of age but showed the opposite in the
older p44tg mice (Fig. 3C and D). This represented a two-
fold increase in b-cell size as the p44tg mice aged from 3 to
12 months. To explore the pathways that regulate b-cell
size, we considered previous reports that proteins in the
insulin/IGF-1 signaling pathways regulate b-cell size via
Akt/mTOR/S6K1 (14–16). Quantitative real-time RT-PCR
for these molecules did not reveal signiﬁcant differences
between groups at 3 months of age except for a decrease
in insulin receptor (IR) expression in p44tg islets (Fig. 3E).
However, in islets from older p44tg mice, we observed in-
creased gene expression of IR, IRS1 (IR substrate-1), and
especially Akt1, mTOR,a n dS6K1,s u g g e s t i n ga na t t e m p t
at compensation by increasing the b-cell size in the older
mutant mice. This was not observed in the liver or white
adipose tissue of p44tg mice (Supplementary Fig. 5).
Examination of islet morphology by immunohisto-
chemistry (Fig. 4A) revealed the typical pattern of a core
of insulin-containing cells surrounded by non–b-cells in
islets from controls and in a majority of islets from p44tg
mice at 3 months of age (Fig. 4A, top). However, ;35%
of islets in the normoglycemic and hypoinsulinemic p44tg
groups exhibited inﬁltration of a- and d-cells within the
islet core and a relative decrease in the number of b-cells
(quantiﬁed in Fig. 4B), which correlated with the hypo-
insulinemia at this age (Fig. 1C). These abnormal fea-
tures, which were not observed at 2 months of age
(Supplementary Fig. 2), were evident in ;85% of the islets
by 12 months of age in the p44tg group (Fig. 4A, bottom).
In parallel, islet hormone gene expression (Fig. 4C)r e v e a l e d
a signiﬁcant increase in somatostatin gene expression that
was consistent with a relative increase in d-cells in p44tg
mice (Fig. 4A), whereas glucagon gene expression (Fig. 4C)
and circulating glucagon levels (Fig. 1D) were not different
between groups at all ages. A signiﬁcant increase in the
expression of insulin and GLUT 2 in 3-month-old trans-
genic mice suggested a compensatory effect at this youn-
ger age (Fig. 4C, top) that was not evident in the older
hyperglycemic group (Fig. 4C, bottom). Because p44tg mice
exhibit hypoinsulinemia and reduced b-cell numbers, we
evaluated b-cell secretory function in vivo (Fig. 4D)a n d
in vitro (Fig. 4E) by measuring insulin release in response
to glucose stimulation. Although in vivo GSIS was im-
paired in p44tg mice (Fig. 4D) and likely contributed
to the glucose intolerance (Fig. 2B) ,t h eG S I Si ni s o l a t e d
islets in vitro was not different between groups (Fig. 4E),
suggesting the absence of a cell autonomous insulin se-
cretory defect.
Inhibition of b-cell proliferation in p44tg mice. Next,
we determined whether the decrease in b-cell mass in
p44tg mice (Fig. 3B) was due to changes in b-cell pro-
liferation. Coimmunostaining of pancreas sections with
antibodies against insulin and either one of two pro-
liferation markers showed a decrease in the proliferation
of b-cells with age in control islets (Fig. 5A and B)a s
reported previously (29). BrdU labeling demonstrated
a virtual absence of replicating b-cells in young and old
p44tg mice compared with controls (Fig. 5A). A decrease
in pHH3 immunoreactive b-cells at 3 and 12–14 months of
age in p44tg mice conﬁrmed reduced number of cells in
the M or late G2 phases of the cell cycle (Fig. 5B). Before
2 months of age, no signiﬁcant difference was evident in
b-cell replication between the two groups (Supplementary
Fig. 2) and correlated with normal glucose tolerance
(Fig. 2).
We next evaluated the effects of neogenesis (30) and
apoptosis (31) in the maintenance of b-cell mass. Single
and clusters (#8) of insulin+ cells (markers of neogenesis)
were virtually absent in pancreatic ducts in 3-month-old
control and p44tg mice. Although some insulin+ cells/
clusters were observed in 12- to 14-month-old mice, no sig-
niﬁcant difference was evident between groups (number/
mm
2 pancreas: 0.3 6 0, control vs. 0.3 6 0.2, p44tg; P = NS,
n=3). Similarly, no signiﬁcant differences were observed
in insulin+ cells in extraductal pancreatic tissue (3 month;
14 6 0.3, control vs. 12.8 6 3.4, p44tg; 12–14 month; 8.3 6
0.2, control vs. 10.2 6 2.4, p44tg; P = NS; n=3), suggesting
that neogenesis is not altered signiﬁcantly when D40p53 is
misexpressed. Although p53 has been studied in the context
of apoptosis in multiple tissues, it has not been causally
involved in b-cell death during diabetes (32). Nevertheless,
we performed the transferase-mediated dUTP nick-end la-
beling (TUNEL) assay and found no signiﬁcant differences
in TUNEL+ b-cells between groups (Supplementary Fig. 3).
These data provide strong evidence that the misexpression
of D40p53 led to a marked reduction of b-cell proliferation,
consistent with reports for other cell types (22,24).
Altered expression of cyclin D2 and PDX-1. p53 regu-
lates the G1 to S phase progression through cell cycle
inhibitors such as p21, but recent reports indicate that p53
also targets integral cell cycle proteins, such as cyclin E
and CDK4 (18). We observed a signiﬁcant decrease in the
gene expression levels of cyclin D2, CDK2, and cyclin E1,
and a signiﬁcant increase in the level of cyclin E2 in
3-month-old p44tg mice (Fig. 6A). At 12 months of age,
described in RESEARCH DESIGN AND METHODS. A representative islet for each group at magniﬁcation 403 is presented with the quantiﬁcation of relative
b-cell size (mean 6 SEM from n ‡200 cells counted per mouse). E: Real-time RT-PCR on RNA extracted from islets of 3- and 10- to 12-month-old
control (n=3–8) and p44tg (n=4) mice. Results are normalized to TATA-binding protein (TBP) and expressed relative to control mice. *P < 0.05
for p44tg vs. control mice. #P < 0.05 for 3- vs. 12- to 14-month-old control mice. §P < 0.05 for 3- vs. 12- to 14-month-old p44tg mice. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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1214 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgFIG. 4. Reduction in insulin-positive cells and increase in somatostatin-positive cells in islets from p44tg mice. A: Triple coimmunostaining for
insulin (blue), somatostatin (green), and glucagon (red) on pancreas sections from control or p44tg mice at 3 and 12–14 months of age as de-
scribed in RESEARCH DESIGN AND METHODS (n=5). Two representative islets for each group at magniﬁcation 403 are presented. B: The number of
insulin-positive cells was counted in at least 10 islets randomly selected from pancreas sections from each mouse (n=3 mice at each age per
group). C: Real-time RT-PCR on RNA extracted from islets of 3- and 10- to 12-month-old control (n=3–8) and p44tg (n=4) mice. Results are
normalized to TBP and expressed relative to controls. D: In vivo GSIS. Insulin was measured in plasma samples extracted from blood collected at
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time, however, CDK4 levels became signiﬁcantly increased.
The decrease in cyclin D2 gene expression at 3 months of
age correlated with lower protein expression in isolated
islets (Fig. 6B, left). In old mice, despite normal levels of
gene expression, cyclin D2 protein level was signiﬁcantly
decreased (Fig. 6B, right).
We next examined the expression of FoxO1, which
regulates b-cell proliferation (33), and two of its target
proteins, PDX-1 (34) and p27 (35). Examination of gene
and protein expression in whole islets revealed that FoxO1
expression was signiﬁcantly lower at 3 months but un-
changed at 10 months in p44tg mice (Fig. 7A and B). PDX-1
gene expression was consistently higher in p44tg mice
(Fig. 7A); however, its protein level was consistently lower
(Fig. 7B). This decrease was less pronounced in old mice
and correlated with fewer b-cells in islets from the trans-
genic mice (Fig. 4B). p27 gene and protein expression
0, 2, and 5 min after intraperitoneal injection of glucose (3 g/kg body wt) from 4–5-month-old control and p44tg mice. E: In vitro GSIS. Islets
isolated from 4–5-month-old control and p44tg mice were incubated for 1 h with 3 or 16.7 mmol/L glucose as described in RESEARCH DESIGN AND
METHODS. Bar graph depicts data obtained from three to ﬁve individual batches of size-matched islets from at least three independent mice per
group. *P < 0.05 for p44tg vs. control mice. #P < 0.05 for 3- vs. 12- to 14-month-old control mice. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
FIG. 5. Reduced b-cell proliferation in p44tg mice. b-Cell proliferation was assessed by coimmunostaining for BrdU (A, green) and pHH3 (B, green)
with insulin (red) and DAPI (blue) in pancreas sections from control and p44tg mice at 3 and 12–14 months of age as described in RESEARCH DESIGN
AND METHODS. A representative islet for each group at magniﬁcation 403 is presented (n=5). Quantiﬁcation is shown on the right.* P < 0.05 for
p44tg vs. control mice. #P < 0.05 for 3- vs. 12- to 14-month-old control mice. (A high-quality digital representation of this ﬁgure is available in the
online issue.)
D40p53 AND b-CELL GROWTH
1216 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgremained unchanged (Fig. 7A and B). These data indicate
that decreased b-cell mass and proliferation observed
in p44tg mice (Figs. 3B and 5) are associated with de-
creased expression of cyclin D2 and PDX-1.
Increased p21 expression in p44tg islets during aging.
Finally, we evaluated the gene expression of p53 and its
protein targets (19). To measure the level of transcription
of both p53 (endogenous) and D40p53 (endogenous and
transgene) genes, we designed two sets of primers for
quantitative RT-PCR because the use of speciﬁc primers to
distinguish both genes was not possible. Np53 primers
targeted the 59 end of the p53 transcript and ampliﬁed
transcripts derived from the endogenous p53 gene only,
whereas Cp53 primers targeted sequences at the 39 end of
RNA and ampliﬁed transcripts derived from both the en-
dogenous p53 gene and the transgene. We also measured
the expression of several well-known p53 target genes
(19), such as p21, 14–3-3, Gadd45, Bax, MDM2, PTEN,
and the IGF-1 receptor (IGF-1R). We observed a signiﬁ-
cant decrease in endogenous p53 gene expression (Np53
FIG. 6. Regulation of cyclin D2 expression in p44tg islets. A: Real time RT-PCR was performed on RNA extracted from islets of 3- and 10- to
12-month-old control (n=3–8) and p44tg (n=4) mice. Results are normalized to TBP and expressed relative to controls. *P < 0.05 for p44tg vs.
control mice. B: Western blotting for cyclin D2 and quantiﬁcation normalized to tubulin in islets from control and p44tg at 3 and 10 months of age.
*P < 0.05 for p44tg vs. control mice.
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islets from 3-month-old p44tg mice (Fig. 8A, top). In islets
from 12-month-old p44tg mice,w eo b s e r v e da ni n c r e a s e
in D40p53 expression (Cp53 primers) that was associ-
ated with an enhanced expression of p21 and MDM2
(Fig. 8A, bottom). Although Bax gene expression was
signiﬁcantly elevated in p44tg islets at both ages, we did
not observe signiﬁcance differences between groups in
the TUNEL assay (Supplementary Fig. 3). The increase
in gene expression of IGF-1R that was evident in young
p44tg islets did not persist in older mice, and we did not
observe alterations in PTEN gene expression at either
age (Fig. 8A). However, we did ﬁnd an increase in p21
protein by Western blot analysis of p44tg islets (Fig. 8B)
and by immunohistochemistry in b- c e l ln u c l e io fp 4 4 t g
islets (Fig. 8C). Thus, the strong inhibition of b-cell
proliferation observed in p44tg islet cells correlated with
as i g n i ﬁcant increase in p21, the main target of p53 in
cell cycle regulation.
DISCUSSION
By using p44tg mice with an ectopic p53 gene that encodes
D40p53 (36), we have identiﬁed a role for the tumor sup-
pressor p53 in the maintenance of normal b-cell mass and
glucose homeostasis. Although D40p53 has virtually no
FIG. 7. Regulation of PDX-1 expression in p44tg islets. A: Real-time RT-PCR was performed on RNA extracted from islets of 3- and 10- to 12-month-
old control (n=3–8) and p44tg (n=4) mice. Results are normalized to TBP and expressed relative to control mice. *P < 0.05 for p44tg vs. control
mice. B: Western blotting for FoxO1, PDX-1, and p27 and quantiﬁcation normalized to tubulin in islets from control and p44tg at 3 and 10 months of
age. *P < 0.05 for p44tg vs. control mice.
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full-length p53 to form tetramers that bind DNA and ac-
tivate or suppress target gene expression (36,37). Ex-
pression of ectopic D40p53 in the mouse alters the
balance between the full-length and short isoforms that
normally exists and hyperactivates p53 (22,36,38). This
increased activity of p53 can account for the higher
levels of p21 transcripts, which we observed in b-cells
from 10–12-month-old p44tg mice. The expression of
D40p53 in p44tg mice can also account for the higher level
of mRNA encoding the IGF-1R, whose transcription is
differentially regulated by wild-type and mutant p53 (39).
An increased gene expression of IGF-1R in liver and white
adipose tissue from p44tg mice (Supplementary Fig. 5)
suggests a non–tissue-speciﬁc effect. Similar to embryonic
ﬁbroblasts derived from p44tg mice (22), islets from young
FIG. 8. Increased p21 expression in p44tg islets. A: Real-time RT-PCR was performed on RNA extracted from islets of 3- and 10- to 12-month-old
control (n=3–8) and p44tg (n=4) mice. Results are normalized to TBP and expressed relative to control mice. *P < 0.05 for p44tg vs. control
mice. B: Western blotting for p21 and quantiﬁcation normalized to actin in islets from control and p44tg at 3 and 10 months of age. *P < 0.05 for
p44tg vs. control mice. C: Quantiﬁcation of p21-positive b-cell nuclei in pancreas sections from control and p44tg mice at 3 and 12–14 months of age
(n=5). *P < 0.05 for p44tg vs. control mice (at least 8–10 islets from ﬁve mice per group).
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indicating impaired trans-suppression activity. Both the
increased trans-activation of p21 in old islets and the de-
creased trans-suppression of the IGF-1R in the young can
be explained by differences in expression of the transgene
encoding D40p53 with age, as detected by primers that
amplify sequences encoding the COOH-terminal domain of
the p53 protein. Younger p44tg mice expressed control
levels of D40p53 and slightly lower levels of p53, whereas
older mice expressed normal levels of p53 and higher
levels of D40p53. Biochemical experiments have demon-
strated that the stability and activity of the p53 tetramer
are exquisitely sensitive to the dose of D40p53, with low
doses of D40p53 activating and high doses inactivating p53
function (40,41). The differential effects of D40p53 on p53-
dependent trans-activation and trans-repression with age
could also explain how p21 levels increase in both age
groups, but by different mechanisms. In old mice, the in-
crease would be due to a direct effect of p53 on the p21
promoter, leading to increased transcription of the p21
gene. In young mice, on the other hand, increased p21 could
be an indirect effect of higher IGF-1R expression and ac-
tivation of IGF signaling due to impaired IGF-1R trans-
repression. Stimulation of the IGF-1 signal transduction
pathway can increase p21 (42), and further work is nec-
essary to delineate the link among D40p53/p53, p21, and
IGF-1R levels in b-cell proliferation.
b-Cell proliferation and glucose tolerance were impaired
in 3-month-old p44tg animals and worsened to overt di-
abetes as the animals aged. Although random-fed blood
glucose levels were normal in the transgenic mice at 3 and
10 months, the mutants displayed clear intolerance in re-
sponse to a glucose challenge indicating deﬁciency in func-
tional b-cells. Previous studies in rodents have reported
normoglycemia even when b-cell mass is reduced. For
example, Sreenan et al. (43) report a reduced b-cell mass
before the onset of diabetes in the nonobese diabetic
mouse, and Tavana et al. (44) describe the phenotypes
of 1-month-old mice doubly mutant for p53 and non-
homologous end-joining deﬁciency that exhibit an ;50%
decrease in b-cell mass and yet manifest blood glucose
levels that are not signiﬁcantly different from controls.
Further, obese and nondiabetic humans have been reported
to express a wide range of b-cell mass that is adequate to
maintain euglycemia up to a speciﬁc threshold, and cross-
ing the threshold correlates with fasting hyperglycemia
and overt diabetes (45). In our study, it is possible that
p44tg mice that are signiﬁcantly leaner than controls at
all ages only cross this “threshold” at ;12 months of age
when they begin to exhibit overt hyperglycemia. Addi-
tional longitudinal studies are necessary to investigate
these observations. Thus, our data suggest that the bal-
ance between full-length and D40p53 isoforms plays a
critical role in the maintenance of b-cell proliferation and
glucose homeostasis, and may be important in regulating
the cell cycle during aging. Further support for a role for
p53 in glucose homeostasis is evident from recent studies.
For example, Minamino et al. (46) reported a role for adi-
pose p53 in the regulation of insulin resistance. In our study,
circulating proinﬂammatory cytokines, which are poten-
tial effectors in insulin resistance associated with diabe-
tes, showed no signiﬁcant differences between groups
(Supplementary Fig. 4). The cytokine expression proﬁle
in liver and white adipose tissue was also similar be-
tween groups. These data, along with the normal insulin
sensitivity in the global p44tg mice, indicate that the
glucose intolerance is due to intrinsic effects of p53 on
b-cell mass rather than to secondary effects of transgene
expression in other insulin sensitive tissues. Indeed, Tavana
et al. (44) reported that DNA double-strand breaks
combined with an absence of p53-dependent apoptosis
in mice leads to reduced b-cell replication and se-
vere age-dependent diabetes, supporting our hypothesis
t h a tp 5 3p l a y sar o l ei nt h er e g u l a t i o no fb-cell pro-
liferation.
Although the mechanisms that regulate the dynamics of
b-cell turnover during aging are still being unraveled,
several studies including our own support a role for rep-
lication as the major mechanism that underlies the com-
pensatory growth response to insulin resistance (1–5,47).
Two proteins that are important for this compensatory
growth response are cyclin D2 (5,11,12) and PDX-1, the
pancreatic duodenal homeobox domain protein (3). The
lower expression of cyclin D2 in islets would potentially
exacerbate the loss of b-cells and lead to glucose in-
tolerance and overt diabetes. In this study, the expression
of PDX-1 was also altered in p44tg b-cells. Although the
gene expression of PDX-1 was increased in both young
and old p44tg mice, the protein expression in islets was
low, suggesting compensatory effects in gene expression
or more dominant regulation of the transcription factor at
the protein level. In old p44tg mice, however, there were
fewer b-cell nuclei in which PDX-1 could be detected.
Immunohistochemistry (data not shown) also revealed
that the localization of PDX-1 correlated inversely with
that of FoxO1, a transcription factor that regulates ex-
pression of this homeodomain protein (34). Because
FoxO1 transactivates cell cycle inhibitors (p21 and p27)
(35) and represses cell cycle activators (cyclin D1 and D2),
nuclear localization of FoxO1 could have a major impact
on cell cycle progression in aging b-cells. Further sub-
cellular fractionation approaches are necessary to directly
address this question. It is also possible that FoxO1 and
p53 interact with deacetylase sirtuin 1 and function in
a cooperative manner in an aging environment (48). Thus,
the alterations in both PDX-1 and cyclin D2, in our model
of accelerated aging, underscore the concept that these
two proteins are involved in b-cell replication during aging.
Two CDKIs, namely, p16 and p19, have been reported to
be involved in b-cell regenerative failure in diabetes (49).
Our observations of enhanced expression of p16 and p19
genes conﬁrm the premature aging phenotype of p44tg
mice (Supplementary Fig. 6). However, the regulatory link
between p53 and the two aging markers in the mainte-
nance or ampliﬁcation of the phenotype requires further
investigation.
Maier et al. (22) previously described that young p44tg
mice displayed signs of aging in bone. Further, the osteoblast-
secreted molecule, osteocalcin, has recently been reported
to modulate insulin secretion and insulin gene expression
that correlated with expression of CREB and NeuroD genes
(50). In our study, we observed a mild but signiﬁcant de-
crease in osteocalcin levels only in old p44tg mice; however,
gene expression of insulin, CREB,o rNeuroD was unaltered
(Supplementary Fig. 7).
Finally, the signiﬁcance of the presence of p53 in non–
b-cell fractions obtained from dispersed islet cells (29)
remains unclear. Although the relative increase in a-cells
in p44tg islets was not associated with an increase in
glucagon gene expression or circulating glucagon levels,
we observed a signiﬁcant increase in the number of
somatostatin-secreting d-cells and gene expression in the
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the somatostatin promoter (Genomatix) warrants further
studies to evaluate whether the increase in somatostatin
actually decreases insulin secretion or limits b-cell growth
in a paracrine manner in the p44tg mice.
In summary, increased dosage of D40p53 in mice pro-
motes hypoinsulinemia and glucose intolerance, ultimately
leading to overt diabetes with age and early death. The
suppression of b-cell proliferation secondary to changes in
the expression of p21, cyclin D2, and PDX-1 in this mouse
model of accelerated aging implicates impaired p53 func-
tion in the development of type 2 diabetes in the elderly.
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